Secukinumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09029 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | primary release disorder of platelets | KG + DL |
| 2 | pseudo-von Willebrand disease | KG + DL |
| 3 | Glanzmann thrombasthenia | KG + DL |
| 4 | HER2 positive breast carcinoma | KG + DL |
| 5 | drug-induced osteoporosis | KG + DL |
| 6 | normal breast-like subtype of breast carcinoma | KG + DL |
| 7 | progesterone-receptor positive breast cancer | KG + DL |
| 8 | breast tumor luminal A or B | KG + DL |
| 9 | progesterone-receptor negative breast cancer | KG + DL |
| 10 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 11 | ankylosing spondylitis | KG + DL |
| 12 | autosomal dominant macrothrombocytopenia | KG + DL |
| 13 | rheumatoid vasculitis | KG + DL |
| 14 | inflammatory spondylopathy | KG + DL |
| 15 | chromhidrosis | KG + DL |
| 16 | hypermobility of coccyx | KG + DL |
| 17 | Kummell disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.